VCAM1 and immunodeficiency disease: Although it is possible that immunodeficiency in the mice might have affected the allograft study, results observed in PKF mice treated with anti-VCAM-1 antibody suggested that immunocompetent mice have similar responses in terms of sVCAM-1 mediated resistance to gemcitabine.